Novartis/Schering AG's Vatalanib Efficacy Not CONFIRMed; Filing Delayed Until 2007

Colorectal cancer agent fails to meet primary endpoint of central radiology review-assessed progression-free survival in the CONFIRM-1 trial, Novartis says. The company expects data on overall survival for the agent, also known as PTK-ZK, to be available in the second half of 2006.